CDC says JN.1 variant accounts for about 62% of COVID cases in US
Reuters
Published Jan 05, 2024 06:46PM ET
Updated Jan 05, 2024 08:10PM ET
(Reuters) - The Centers for Disease Control and Prevention (CDC) said on Friday that COVID subvariant JN.1 accounts for about 62% of cases in the U.S. as of Jan. 5, according to the agency's projections.
The agency said JN.1, which is an offspring of BA.2.86, is now the most widely circulated variant in the U.S. and globally.
It is also the dominant variant in Europe and is rising sharply in Asia, the CDC said.
The predicted range of 55% to 68% of cases is an increase from the estimated prevalence of 39% to 50% of cases in the U.S. projected by the CDC as of Dec. 23.
The CDC said currently there is no evidence that JN.1 causes more severe disease and added current vaccines are expected to increase protection against JN.1.
COVID-19 hospitalizations increased 20.4% in the week ended Dec. 30, the CDC said.
In December, the World Health Organization classified JN.1 as a "variant of interest" and said current evidence shows risk to public health was low from the strain.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.